AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reiterated by research analysts at Liberum Capital in a note issued to investors on Friday, May 12th. They currently have a GBX 5,100 ($64.52) price target on the biopharmaceutical company’s stock. Liberum Capital’s target price would indicate a potential downside of 3.48% from the company’s current price.
Several other equities analysts have also recently commented on the stock. Goldman Sachs Group, Inc. (The) cut their target price on shares of AstraZeneca plc from GBX 4,000 ($50.60) to GBX 3,900 ($49.34) and set a “sell” rating for the company in a research note on Tuesday, January 24th. Investec assumed coverage on shares of AstraZeneca plc in a research note on Monday, January 23rd. They set a “hold” rating and a GBX 4,600 ($58.19) target price for the company. HSBC Holdings plc restated a “hold” rating and issued a GBX 4,700 ($59.46) price objective on shares of AstraZeneca plc in a research note on Wednesday, January 25th. Jefferies Group LLC restated a “buy” rating and issued a GBX 5,400 ($68.31) price objective on shares of AstraZeneca plc in a research note on Friday, January 13th. Finally, Beaufort Securities restated a “hold” rating on shares of AstraZeneca plc in a research note on Wednesday, January 18th. Five analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of GBX 5,121.80 ($64.79).
Shares of AstraZeneca plc (AZN) traded up 0.02% during midday trading on Friday, hitting GBX 5284.00. 3,878,930 shares of the stock traded hands. The firm has a 50-day moving average price of GBX 5,087.18 and a 200 day moving average price of GBX 4,684.86. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00. The stock’s market cap is GBX 66.90 billion.
WARNING: This article was published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://transcriptdaily.com/2017/06/17/astrazeneca-plc-azn-earns-buy-rating-from-liberum-capital-updated-updated-updated.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.